Cytokinetics (CYTK) Competitors $49.86 -1.23 (-2.41%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CYTK vs. RNA, CNST, ZGNX, ICPT, PHAT, TEVA, BGNE, VTRS, SMMT, and MRNAShould you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include Avidity Biosciences (RNA), Constellation Pharmaceuticals (CNST), Zogenix (ZGNX), Intercept Pharmaceuticals (ICPT), Phathom Pharmaceuticals (PHAT), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), Summit Therapeutics (SMMT), and Moderna (MRNA). These companies are all part of the "medical" sector. Cytokinetics vs. Avidity Biosciences Constellation Pharmaceuticals Zogenix Intercept Pharmaceuticals Phathom Pharmaceuticals Teva Pharmaceutical Industries BeiGene Viatris Summit Therapeutics Moderna Cytokinetics (NASDAQ:CYTK) and Avidity Biosciences (NASDAQ:RNA) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership. Do analysts prefer CYTK or RNA? Cytokinetics presently has a consensus price target of $83.67, indicating a potential upside of 67.80%. Avidity Biosciences has a consensus price target of $63.22, indicating a potential upside of 44.84%. Given Cytokinetics' higher probable upside, equities analysts plainly believe Cytokinetics is more favorable than Avidity Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytokinetics 0 Sell rating(s) 4 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.75Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, CYTK or RNA? Cytokinetics has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Is CYTK or RNA more profitable? Avidity Biosciences has a net margin of -2,772.45% compared to Cytokinetics' net margin of -17,906.25%. Cytokinetics' return on equity of 0.00% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cytokinetics-17,906.25% N/A -50.21% Avidity Biosciences -2,772.45%-27.66%-24.56% Does the media prefer CYTK or RNA? In the previous week, Cytokinetics had 10 more articles in the media than Avidity Biosciences. MarketBeat recorded 24 mentions for Cytokinetics and 14 mentions for Avidity Biosciences. Cytokinetics' average media sentiment score of 0.41 beat Avidity Biosciences' score of 0.38 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 7 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avidity Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, CYTK or RNA? Avidity Biosciences has higher revenue and earnings than Cytokinetics. Avidity Biosciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytokinetics$3.22M1,827.95-$526.24M-$5.38-9.27Avidity Biosciences$9.56M544.76-$212.22M-$2.88-15.16 Does the MarketBeat Community favor CYTK or RNA? Cytokinetics received 648 more outperform votes than Avidity Biosciences when rated by MarketBeat users. Likewise, 79.64% of users gave Cytokinetics an outperform vote while only 67.25% of users gave Avidity Biosciences an outperform vote. CompanyUnderperformOutperformCytokineticsOutperform Votes80279.64% Underperform Votes20520.36% Avidity BiosciencesOutperform Votes15467.25% Underperform Votes7532.75% SummaryCytokinetics beats Avidity Biosciences on 9 of the 16 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTK vs. The Competition Export to ExcelMetricCytokineticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.88B$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-9.2710.57134.3717.77Price / Sales1,827.95243.641,158.6875.18Price / CashN/A22.1633.5332.53Price / Book-12.655.474.674.68Net Income-$526.24M$153.61M$119.07M$226.08M7 Day Performance-8.85%-2.00%-1.83%-1.04%1 Month Performance-7.34%-7.47%-3.62%1.04%1 Year Performance57.09%31.80%31.63%26.28% Cytokinetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTKCytokinetics3.8052 of 5 stars$49.86-2.4%$83.67+67.8%+54.3%$5.88B$3.22M-9.27250Analyst ForecastInsider TradeOptions VolumeNews CoverageRNAAvidity Biosciences2.3883 of 5 stars$43.65+0.9%$63.22+44.8%+631.2%$5.16B$9.56M0.00190Insider TradeAnalyst RevisionCNSTConstellation PharmaceuticalsN/A$33.99flatN/AN/A$1.63BN/A-12.10154ZGNXZogenixN/A$26.68flatN/A+0.0%$1.50B$81.69M-6.56218ICPTIntercept PharmaceuticalsN/A$19.00flatN/AN/A$794.77M$285.71M-12.84341PHATPhathom Pharmaceuticals2.3223 of 5 stars$8.73-6.8%$22.50+157.7%+17.8%$640.70M$680,000.00-1.53110TEVATeva Pharmaceutical Industries2.6924 of 5 stars$17.03+1.2%$19.67+15.5%+80.0%$19.04B$15.85B0.0037,851BGNEBeiGene3.174 of 5 stars$194.26+3.5%$247.07+27.2%+3.4%$18.92B$2.46B-23.5810,600Analyst DowngradeGap UpVTRSViatris1.3448 of 5 stars$13.13+0.6%$13.33+1.5%+38.6%$15.58B$15.43B0.0038,000SMMTSummit Therapeutics1.863 of 5 stars$18.62-6.9%$34.75+86.6%+835.7%$14.75B$700,000.000.00105Analyst ForecastMRNAModerna4.6286 of 5 stars$36.94-0.9%$84.00+127.4%-53.2%$14.35B$6.85B0.005,600Analyst UpgradeAnalyst Revision Related Companies and Tools Related Companies Avidity Biosciences Alternatives Constellation Pharmaceuticals Alternatives Zogenix Alternatives Intercept Pharmaceuticals Alternatives Phathom Pharmaceuticals Alternatives Teva Pharmaceutical Industries Alternatives BeiGene Alternatives Viatris Alternatives Summit Therapeutics Alternatives Moderna Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYTK) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYTK Stock Alerts